Gastroprotection in NSAID and low-dose aspirin users: A cross-sectional study in primary care

Gastroenterologia y Hepatologia

Volumn 35, Issue 1, 2012, Pages 1-7

  Lanas, Angel ^a   Plazas, Ma Josep ^b   Gimeno, Eva ^c   Muñoz Tudurí, Marta ^d  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b Laboratorios Almirall SA ^*  (Spain)

^c Biometría Clínica S L   (Spain)

^d TFS Develop   (Spain)

Author keywords

Anti inflammatory agents; Aspirin; Gastrointestinal disorders; Non steroidal; Prevention and control; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENERAL PRACTITIONER; HEALTH CARE UTILIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVENTIVE HEALTH SERVICE; PRIMARY MEDICAL CARE; STOMACH PROTECTION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CROSS-SECTIONAL STUDIES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 84856244712     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2011.10.004     Document Type: Article

References (27)

1. Corredor M.T., García E., álvarez J., Roldán R. Prescribimos antiinflamatorios no esteroideos (AINEs) pero... ¿y la protección gástrica?. Medifam 2002, 12:69-71.
2. Ansara A.J., Nisly S.A., Arif S.A., Koehler J.M., Nordmeyer S.T. Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. Ann Pharmacoth 2010, 44:851-862.
3. Lanas A., Perez-Aisa M.A., Feu F., Ponce J., Saperas E., Santolaria S., et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005, 100:1685-1693.
4. Lanza F.L., Chan F.K., Quigley E.M. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009, 104:728-738.
5. Lanas A., Martin-Mola E., Ponce J., Navarro F., Piqué J.M., Blanco F.J. Recomendaciones de la Asociación Española de Gastroenterología y de la Sociedad Española de Reumatología, Estrategia clínica para la prevención de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideos. Gastroenterol Hepatol 2003, 26:485-502.
6. Wilcox C.M., Allison J., Benzuly K., Borum M., Cryer B., Grosser T., et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006, 4:1082-1089.
7. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
8. Zhang W., Doherty M., Leeb B.F., Alekseeva L., Arden N.K., Bijlsma J.W., et al. EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis 2009, 68:8-17.
9. Sturkenboom M.C., Burke T.A., Dieleman J.P., Tangelder M.J., Lee F., Goldstein J. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003, 42(Suppl. 3):iii23-iii31.
10. Moore R.A., Derry S., Phillips C.J., McQuay H.J. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006, 7:79.
11. Vonkeman H.E., Fernandes R.W., van de Laar M.A. Under-utilization of gastroprotective drugs in patients with NSAID-related ulcers. Int J Clin Pharmacol Ther 2007, 45:281-288.
12. Goldstein J.L., Howard K.B., Walton S.M., McLaughlin T.P., Kruzikas D.T. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006, 4:1337-1345.
13. Lanas A., Esplugues J.V., Zapardiel J., Sobreviela E. Education-based approach to addressing non-evidence-based practice in preventing NSAID-associated gastrointestinal complications. World J Gastroenterol 2009, 15:5953-5959.
14. Lanas A., Tornero J., Zamorano J.L. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010, 69:1453-1458.
15. García-Rodríguez L.A., Hernández-Diaz S., De Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001, 52:563-571.
16. Lanas A., Munoz M., Caballero C.M., Martinez J.P. Analysis of differences between indication and prescription of gastroprotection in patients with risk factors treated with nonsteroidal anti-inflammatory agents: the GAP study. Gastroenterol Hepatol 2010, 33:80-91.
17. Burrull M., Madridejos R., Gregori A., Busquets E. Antiinflamatorios no esteroideos y protección gastrointestinal: ¿prescripción adecuada en atención primaria?. Atención Primaria 1996, 18:507-510.
18. Herings R.M., Goettsch W.G. Inadequate prevention of NSAID-induced gastrointestinal events. Ann Pharmaco Ther 2004, 38:760-763.
19. Carvajal A., Martín L.H., Vega E., García J.A., Martín I., García P. Gastroprotection during the administration of non-steroidal anti-inflammatory drugs. A drug-utilization study. Eur J Clin Pharmacol 2004, 60:439-444.
20. Lanas A. Update on gastrointestinal disorders associated with non-steroidal anti-inflammatory drugs. Gastroenterol Hepatol 2008, 31(Suppl. 4):35-41.
21. Casado R., Polo-Tomas M., DelRio A.M., Scheiman J., Lanas A. Prescription rates of PPI therapy are high in patients on dual antiplatelet therapy in Spain, regardless of the presence of risk factors. Gastroenterology 2009, 136(Suppl. 1):A-A69.
22. Valkhoff V.E., van Soest E.M., Sturkenboom M.C., Kuipers E.J. Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharmacol Ther 2010, 31:1218-1228.
23. Labenz J., Petersen K.U., Rösch W., Koelz H.R. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2003, 17:1015-1019.
24. Laheij R.J., Sturkenboom M.C., Hassing R.J., Dieleman J., Stricker B.H., Jansen J.B. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. J Am Med Assoc 2004, 292:1955-1960.
25. Canani R.B., Cirillo P., Roggero P., Romano C., Malamisura B., Terrin G., et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006, 117:e817-e820.
26. Yang Y.X., Lewis J.D., Epstein S., Metz D.C. Long-term proton pump inhibitor therapy and risk of hip fracture. J Am Med Assoc 2006, 296:2947-2953.
27. Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007, 102:2047-2056.